Your browser doesn't support javascript.
loading
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Bardia, A; Tolaney, S M; Punie, K; Loirat, D; Oliveira, M; Kalinsky, K; Zelnak, A; Aftimos, P; Dalenc, F; Sardesai, S; Hamilton, E; Sharma, P; Recalde, S; Gil, E C; Traina, T; O'Shaughnessy, J; Cortes, J; Tsai, M; Vahdat, L; Diéras, V; Carey, L A; Rugo, H S; Goldenberg, D M; Hong, Q; Olivo, M; Itri, L M; Hurvitz, S A.
Affiliation
  • Bardia A; Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Loirat D; Medical Oncology Department and D3i, Institut Curie, Paris, France.
  • Oliveira M; Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Kalinsky K; Columbia University Irving Medical Center, New York, USA; Winship Cancer Institute, Emory University, Atlanta, USA.
  • Zelnak A; Northside Hospital, Atlanta, USA.
  • Aftimos P; Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.
  • Dalenc F; Institut Claudius Regaud, Toulouse, France.
  • Sardesai S; The Ohio State University Wexner Medical Center, Columbus, USA.
  • Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.
  • Sharma P; University of Kansas Medical Center, Westwood, USA.
  • Recalde S; Institut Catala d'Oncologia Hospitalet, Barcelona, Spain.
  • Gil EC; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Traina T; Memorial Sloan Kettering Cancer Center, New York, USA.
  • O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.
  • Cortes J; International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Spain.
  • Tsai M; VPCI Oncology Research, Minneapolis, USA.
  • Vahdat L; MSK-Norwalk Hospital Partnership, Norwalk, USA.
  • Diéras V; Centre Eugène Marquis, Rennes, France.
  • Carey LA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
  • Rugo HS; University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.
  • Goldenberg DM; Immunomedics, Inc., Morris Plains, USA; Center for Molecular Medicine and Immunology, Mendham, USA.
  • Hong Q; Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.
  • Olivo M; Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.
  • Itri LM; Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.
  • Hurvitz SA; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, USA. Electronic address: shurvitz@mednet.ucla.edu.
Ann Oncol ; 32(9): 1148-1156, 2021 09.
Article in En | MEDLINE | ID: mdl-34116144
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoconjugates / Triple Negative Breast Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Ann Oncol Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoconjugates / Triple Negative Breast Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Ann Oncol Year: 2021 Document type: Article